9 Európai 7-es keretprogram támogatott témáiTémaCélok€ billion%1. HealthDNA sequencing, tissue, cell and gene therapies, as well as biotech medicines6.1182. Food, agriculture, fisheries and biotechnologyEuropeanKnowledge Based Bio- Economy (KBBE) (food, feed, forest, fisheries, agriculture, aquaculture, chemistry1.963. Information andCommunicationBioinformatics, personal healthcare, computer power to speed up DNA sequencing plus research into ‘Future and emerging technologies9,1274. Nanoscienceget to the bottom of a disease, and develop and integrate new technologies and materials.3.4105. EnergyA major opportunity for biotech. From the development of bio refineries to marine biomas2.376. Environmentemphasize the sustainable management of resources, climate change, pollution, and conservation.1.857. Transportsafer, 'greener' and 'smarter' pan European transport systems that will benefit all citizens, respect the environment, and increase the competitiveness of European industries in the global market.4.1128: Socio-economic Sciences and HumanitiesEvery technological development has a societal consequence. Opportunities especially for National Association led projects like BioImpact, EuroBioJobs portal, BioLife TV, BioPicture Festival.9: SpaceBiotech can support the EU’s long term needs, including space transportation (biofuels), bio-medicine, life and physical sciences in space1.4410: SecurityThe biotech industry contributes to the safety of citizens not only by developing detection technologies and the knowledge needed to ensure security, but also by producing biomedical vaccines.9

39 Incidence of pseudoallergy2.2 million adverse drug reactions with 106,000 fatalities per year represents the 4th to 6th leading cause of death in the USA.25 % of all adverse drug reactions is allergic in nature. Lazarou et al., JAMA, 279;1200, 199877% of all allergic drug reactions is not true allergy. Demoly et al., Allergy, 54;500, 1999420,000 pseudoallergic reactions with 20,000 fatalities/year (?)

41 Hypersensitivity to Doxil and C activation in human sera in vitroDoxil package insertWARNING: Acute infusion-related reactions, sometimes reversible upon terminating or slowing infusion, occurred in up to 10% of patients. Serious and sometimes fatal allergic/anaphylactoid-like infusion reactions have been reported. Medications/ emergency equipment to treat such reactions should be available for immediate use ...” Source: .comJ. Liposome Res. 10: , 2000

42 Hypersensitivity to Ambisome and C activation in human sera in vitroN = 20 NHSSerum onlyVehicle (PBS)ZymosanAmbisome100200300400500*SC5b-9 (ng/mL)WARNINGSAnaphylaxis has been reported with amphotericin B deoxycholate and other amphotericin B-containing drugs, including AmBisome. If a severe anaphylactic reaction occurs, the infusion should be immediately discontinued and the patient should not receive further infusions of AmBisome.

44 Hypersensitvity to Taxol and C activation in human sera in vitroTaxol package insertWARNINGTAXOL® (paclitaxel) should be administered under the supervision of a physicianexperienced in the use of cancer chemotherapeutic agents. Appropriate management ofcomplications is possible only when adequate diagnostic and treatment facilities arereadily available. Anaphylaxis and severe hypersensitivity reactions characterized by dyspnea and hypotension requiring treatment, angioedema, and generalized urticaria have occurred in 2 to 4% of patients receiving TAXOL in clinical trials. Fatal reactions have occurred in patients despite premedication. All patients should be pretreated with corticosteroids, diphenhydramine, and H2 antagonists.Patients who experience severe hypersensitivity reactions to TAXOL should not berechallenged with the drug.PBSTaxolJ Natl Cancer Inst. 90: , 1998Intern. Immunopharm. 1: , 2001

45 Hypersensitivity to Taxotere and C activation in human sera in vitroSevere hypersensitivity reactions characterized by generalized rash/erythema, hypotension and/or bronchospasm, or very rarely fatal anaphylaxis, have been reported in patients who received the recommended 3-day dexamethasone premedication. Hypersensitivity reactions require immediate discontinuation of the TAXOTERE infusion and administration of appropriate therapy. TAXOTERE must not be given to patients who have a history of severe hypersensitivity reactions to TAXOTERE or to other drugs formulated with polysorbate 80